Who are Vitamin D tablets's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pregvit®, Gabapentin/B-complex, Amlodipine besylate and folic acid, Enalapril maleate and folic acid tablets, B Vitamins, i.m. injection of vitamin B12.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vitamin-d-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Vitamin D tablets — Competitive Intelligence Brief

Vitamin D tablets (Vitamin D tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vitamin supplement. Area: Nutritional supplementation / Bone health.

marketed Vitamin supplement Vitamin D receptor (VDR) Nutritional supplementation / Bone health Small molecule Live · refreshed every 30 min

Target snapshot

Vitamin D tablets (Vitamin D tablets) — Ain Shams University. Vitamin D tablets provide cholecalciferol (vitamin D3) to regulate calcium and phosphate homeostasis and support immune and bone health.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Vitamin D tablets TARGET	Vitamin D tablets	Ain Shams University	marketed	Vitamin supplement	Vitamin D receptor (VDR)
Pregvit®	Pregvit®	The Hospital for Sick Children	marketed	Prenatal vitamin supplement
Gabapentin/B-complex	Gabapentin/B-complex	Merck KGaA, Darmstadt, Germany	marketed	Anticonvulsant/analgesic combination with vitamin supplementation	Alpha-2-delta subunit of voltage-gated calcium channels (gabapentin component)
Amlodipine besylate and folic acid	Amlodipine besylate and folic acid	Shenzhen Ausa Pharmed Co.,Ltd	marketed	Calcium channel blocker + B vitamin supplement	L-type calcium channel (amlodipine); dihydrofolate reductase (folic acid)
Enalapril maleate and folic acid tablets	Enalapril maleate and folic acid tablets	Shenzhen Ausa Pharmed Co.,Ltd	marketed	ACE inhibitor (combination with vitamin supplement)	Angiotensin-converting enzyme (ACE)
B Vitamins	B Vitamins	Fundação Educacional Serra dos Órgãos	marketed	Vitamin supplement
i.m. injection of vitamin B12	i.m. injection of vitamin B12	University Hospital, Basel, Switzerland	marketed	Vitamin supplement / Essential nutrient	Methionine synthase, methylmalonyl-CoA mutase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vitamin supplement class)

Ain Shams University · 1 drug in this class
CHU de Quebec-Universite Laval · 1 drug in this class
First Affiliated Hospital Xi'an Jiaotong University · 1 drug in this class
Fundação Educacional Serra dos Órgãos · 1 drug in this class
M.D. Anderson Cancer Center · 1 drug in this class
Washington University School of Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vitamin D tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/vitamin-d-tablets. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab